Recurrence in early gastric cancer--presence of micrometastasis in lymph node of node negative early gastric cancer patient with recurrence. 2007

Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
Department of Surgery, Division of Surgical Oncology, Tottori University School of Medicine, Yonago, Japan. sai10@grape.med.tottori-u.ac.jp

OBJECTIVE There are cases of recurrence even after curative resection in early gastric cancer. METHODS Seven hundred and sixty-five patients with early gastric cancer who underwent curative gastrectomy were analyzed to identify the prognostic factor. Micrometastases within lymph nodes were determined by immunohistochemistry using anti-cytokeratin antibody in node-negative early gastric cancer patients with recurrence. RESULTS The recurrence was observed in 17 patients. Hematogenous recurrence was observed most frequently (47.1%), followed by peritoneal recurrence (23.5%). Of 17 patients with recurrence, 6 (35.3%) patients died more than 5 years after operation. The prognosis was poorer when the patients were older, and the depth of invasion was greater, lymph node metastasis, lymphatic involvement, and vascular involvement were present, and lymph node dissection was limited. The independent prognostic factors were lymph node metastasis, lymph node dissection, and age by multivariate analysis using Cox proportional hazards. Micrometastases within lymph nodes were confirmed in 3 of 6 node-negative patients with recurrence. CONCLUSIONS When patients have lymph node metastases or are older, close and long-term follow-up and careful planning of postoperative adjuvant therapy might be necessary to avoid recurrence. The detection of micrometastases by anti-cytokeratin antibody might be useful for predicting the possibility of recurrence in early gastric cancer.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D007633 Keratins A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION. Cytokeratin,Keratin Associated Protein,Keratin,Keratin-Associated Proteins,alpha-Keratin,Associated Protein, Keratin,Keratin Associated Proteins,Protein, Keratin Associated,alpha Keratin
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009360 Neoplastic Cells, Circulating Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors. Circulating Neoplastic Cells,Embolic Tumor Cells,Embolism, Tumor,Neoplasm Circulating Cells,Tumor Cells, Embolic,Cells, Neoplasm Circulating,Circulating Cells, Neoplasm,Circulating Tumor Cells,Cell, Circulating Neoplastic,Cell, Circulating Tumor,Cell, Embolic Tumor,Cell, Neoplasm Circulating,Cells, Circulating Neoplastic,Cells, Circulating Tumor,Cells, Embolic Tumor,Circulating Neoplastic Cell,Circulating Tumor Cell,Embolic Tumor Cell,Embolisms, Tumor,Neoplasm Circulating Cell,Neoplastic Cell, Circulating,Tumor Cell, Circulating,Tumor Cell, Embolic,Tumor Cells, Circulating,Tumor Embolism,Tumor Embolisms
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm

Related Publications

Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
April 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
October 2002, Annals of surgical oncology,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
April 2020, Mathematical biosciences and engineering : MBE,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
March 2015, Annals of surgical oncology,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
January 2008, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
September 2017, Updates in surgery,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
January 2011, Digestive surgery,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
February 2013, Annals of surgical oncology,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
August 2017, Oncotarget,
Hiroaki Saito, and Tomohiro Osaki, and Daiki Murakami, and Teruhisa Sakamoto, and Shingo Kanaji, and Shotaro Ohro, and Shigeru Tatebe, and Shunichi Tsujitani, and Masahide Ikeguchi
July 2002, Gynecologic oncology,
Copied contents to your clipboard!